Green tea catechins: Defensive role in cardiovascular disorders

Chinese Journal of Natural Medicines

Volumn 11, Issue 4, 2013, Pages 345-353

  Bhardwaj, Pooja ^a   Khanna, Deepa ^a  

^a Rajendra Institute of Technology and Sciences   (India)

Author keywords

Cardiovascular disorders; Green tea catechins; Nitric oxide; Reactive oxygen species; Vascular cell adhesion molecule 1

Indexed keywords

CATECHIN; CELL ADHESION MOLECULE; CYTOKINE; FREE RADICAL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD PRESSURE REGULATION; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CELL PROLIFERATION; CONGESTIVE HEART FAILURE; CYTOKINE PRODUCTION; DRUG BIOAVAILABILITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME INHIBITION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INFLAMMATORY DISEASE; ISCHEMIC HEART DISEASE; NONHUMAN; OXIDATIVE STRESS; TEA; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; VASCULAR SMOOTH MUSCLE;

EID: 84879997620     PISSN: 20956975     EISSN: 18755364     Source Type: Journal    
DOI: 10.1016/S1875-5364(13)60051-5     Document Type: Article

References (93)

1. Graham HN Green tea composition, consumption, and polyphenol chemistry [J]. Prev Med 1992, 21(3):334-350.
2. Sang S, Lambert JD, Ho CT, et al. The chemistry and biotransformation of tea constituents [J]. Pharmacol Res 2011, 64(2):87-99.
3. Cabrera C, Artacho R, Giménez R Beneficial effects of green tea - a review [J]. J Am Coll Nutr 2006, 25(2):79-99.
4. Balentine DA, Wiseman SA, Bouwens LC The chemistry of tea flavonoids [J]. Crit Rev Food Sci Nutr 1997, 37(8):693-704.
5. Henning SM, Fajardo-Lira C, Lee HW, et al. Catechin content of 18 teas and a green tea extract supplement correlates with the antioxidant capacity [J]. Nutr Cancer 2003, 45(2):226-235.
6. Kimura M, Umegaki K, Kasuya Y, et al. The relation between single/double or repeated tea catechin ingestions and plasma antioxidant activity in humans [J]. Eur J Clin Nutr 2002, 56(12):1186-1193.
7. Cabrera C, Giménez R, López MC Determination of tea components with antioxidant activity [J]. J Agric Food Chem 2003, 51(15):4427-4435.
8. Kuroda Y, Hara Y Antimutagenic and anticarcinogenic activity of tea polyphenols [J]. Mutat Res 1999, 436(1):69-97.
9. Isozaki T, Tamura H Epigallocatechin gallate (EGCG) inhibits the sulfation of 1-naphthol in a human colon carcinoma cell line, Caco-2 [J]. Biol Pharm Bull 2001, 24(9):1076-1078.
10. Valcic S, Timmermann BN, Alberts DS, et al. Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell lines [J]. Anticancer Drugs 1996, 7(4):461-468.
11. Lee IP, Kim YH, Kang MH, et al. Chemopreventive effect of green tea (Camellia sinensis) against cigarette smoke-induced mutations (SCE) in humans [J]. J Cell Biochem Suppl 1997, 27(1):68-75.
12. Rizvi SI, Zaid MA Intracellular reduced glutathione content in normal and type 2 diabetic erythrocytes: effect of insulin and (-)-epicatechin [J]. J Physiol Pharmacol 2001, 52(3):483-488.
13. Nagao T, Komine Y, Soga S, et al. Ingestion of a tea rich in catechins leads to a reduction in body fat and malondialdehyde-modified LDL in men [J]. Am J Clin Nutr 2005, 81(1):122-129.
14. WHO World Health Statistics 2009[M] 2009, World Health Organization, Geneva.
15. Kuriyama S, Shimazu T, Ohmori K, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study [J]. JAMA 2006, 296(10):1255-1265.
16. Sasazuki S, Kodama H, Yoshimasu K, et al. Relation between green tea consumption and the severity of coronary atherosclerosis among Japanese men and women [J]. Ann Epidemiol 2000, 10(6):401-408.
17. Hernández Figueroa TT, Rodríguez-Rodríguez E, Sánchez-Muniz FJ The green tea, a good choice for cardiovascular disease prevention [J]. Arch Latinoam Nutr 2004, 54(4):380-394.
18. Babu PV, Liu D Green tea catechins and cardiovascular health: an update [J]. Curr Med Chem 2008, 15(18):1840-1850.
19. Islam MA Cardiovascular effects of green tea catechins: progress and promise [J]. Recent Pat Cardiovasc Drug Discov 2012, 7(2):88-99.
20. Dhalla NS, Temsah RM, Netticadan T Role of oxidative stress in cardiovascular diseases [J]. J Hypertens 2000, 18(6):655-673.
21. Park J, Lee J, Choi C Mitochondrial network determines intracellular ROS dynamics and sensitivity to oxidative stress through switching inter-mitochondrial messengers [J]. PLoS One 2011, 6(8):e23211.
22. Paravicini TM, Touyz RM NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities [J]. Diabetes Care 2008, 31(Suppl 2):S170-S180.
23. Zinkevich NS, Gutterman DD ROS-induced ROS release in vascular biology: redox-redox signaling [J]. Am J Physiol Heart Circ Physiol 2011, 301(3):H647-H653.
24. Heim KE, Tagliaferro AR, Bobilya DJ Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships [J]. J Nutr Biochem 2002, 13(10):572-584.
25. Yamabe N, Yokozawa T, Oya T, et al. Therapeutic potential of (-)-epigallocatechin 3-O-gallate on renal damage in diabetic nephropathy model rats [J]. J Pharmacol Exp Ther 2006, 319(1):228-236.
26. Frei B, Higdon JV Antioxidant activity of tea polyphenols in vivo: evidence from animal studies [J]. J Nutr 2003, 133(10):3275S-3284S.
27. Agarwal A, Prasad R, Jain A Effect of green tea extract (catechins) in reducing oxidative stress seen in patients of pulmonary tuberculosis on DOTS Cat I regimen [J]. Phytomedicine 2010, 17(1):23-27.
28. Zheng J, Lee HC, Bin Sattar MM, et al. Cardioprotective effects of epigallocatechin-3-gallate against doxorubicin-induced cardiomyocyte injury [J]. Eur J Pharmacol 2011, 652(1-3):82-88.
29. Miura Y, Chiba T, Tomita I, et al. Tea catechins prevent the development of atherosclerosis in apoprotein E-deficient mice [J]. J Nutr 2001, 131(1):27-32.
30. Libby P Inflammation and cardiovascular disease mechanisms [J]. Am J Clin Nutr 2006, 83(2):456S-460S.
31. Mayer K, Merfels M, Muhly-Reinholz M, et al. Omega-3 fatty acids suppress monocyte adhesion to human endothelial cells: role of endothelial PAF generation [J]. Am J Physiol Heart Circ Physiol 2002, 283(2):H811-H818.
32. Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice [J]. Mol Cell 1998, 2(2):275-281.
33. Marui N, Offermann MK, Swerlick R, et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells [J]. J Clin Invest 1993, 92(4):1866-1874.
34. Kevil CG, Patel RP, Bullard DC Essential role of ICAM-1 in mediating monocyte adhesion to aortic endothelial cells [J]. Am J Physiol Cell Physiol 2001, 281:C1442-C1447.
35. Gerszten RE, Garcia-Zepeda EA, Lim YC, et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions [J]. Nature 1999, 398(6729):718-723.
36. Qiao JH, Tripathi J, Mishra NK, et al. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice [J]. Am J Pathol 1997, 150(5):1687-1699.
37. Brånén L, Hovgaard L, Nitulescu M, et al. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice [J]. Arterioscler Thromb Vasc Biol 2004, 24(11):2137-2142.
38. Lin YL, Lin JK (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappa B [J]. Mol Pharmacol 1997, 52(3):465-472.
39. Suzuki J, Ogawa M, Izawa A, et al. Dietary consumption of green tea catechins attenuate hyperlipidaemia-induced atherosclerosis and systemic organ damage in mice [J]. Acta Cardiol 2005, 60(3):271-276.
40. Suzuki J, Ogawa M, Futamatsu H, et al. Tea catechins improve left ventricular dysfunction, suppress myocardial inflammation and fibrosis, and alter cytokine expression in rat autoimmune myocarditis [J]. Eur J Heart Fail 2007, 9(2):152-159.
41. Ludwig A, Lorenz M, Grimbo N, Steinle F, et al. The tea flavonoid epigallocatechin-3-gallate reduces cytokine-induced VCAM-1 expression and monocyte adhesion to endothelial cells [J]. Biochem Biophys Res Commun 2004, 316:659-665.
42. Liang OD, Kleibrink BE, Schuette-Nuetgen K, et al. Green tea epigallo-catechin-galleate ameliorates the development of obliterative airway disease [J]. Exp Lung Res 2011, 37(7):435-444.
43. Aird WC Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms [J]. Circ Res 2007, 100(2):158-173.
44. Galley HF, Webster NR Physiology of the endothelium [J]. Br J Anaesth 2004, 93(1):105-113.
45. Schiffrin EL A critical review of the role of endothelial factors in the pathogenesis of hypertension [J]. J Cardiovasc Pharmacol 2001, 38:S3-S6.
46. Balakumar P, Chakkarwar VA, Krishan P, et al. Vascular endothelial dysfunction: a tug of war in diabetic nephropathy [J]?. Biomed Pharmacother 2009, 63(3):171-179.
47. Forstermann U, Munzel T Endothelial nitric oxide synthase in vascular disease: from marvel to menace [J]. Circulation 2006, 113(13):1708-1714.
48. Dimmeler S, Fleming I, Fisslthaler B, et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation [J]. Nature 1999, 399(6736):601-605.
49. Kobayashi T, Matsumoto T, Kamata K The PI3-K/Akt pathway: roles related to alterations in vasomotor responses in diabetic model [J]. J Smooth Muscle Res 2005, 41(6):283-302.
50. Hadi HAR, Carr CS, Al Suwaidi J Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome [J]. Vasc Health Risk Manag 2005, 1(3):183-198.
51. Lorenz M, Wessler S, Follmann E, et al. A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation [J]. J Biol Chem 2004, 279(7):6190-6195.
52. Potenza MA, Marasciulo FL, Tarquinio M, et al. EGCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR [J]. Am J Physiol Endocrinol Metab 2007, 292(5):E1378-E1387.
53. Mizugaki M, Ishizawa F, Yamazaki T, et al. Epigallocatechin gallate increases the prostacyclin production of bovine aortic endothelial cells [J]. Prostaglandins Other Lipid Mediat 2000, 62(2):157-164.
54. Landim MB, Casella Filho A, Chagas AC Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis [J]. Clinics (Sao Paulo) 2009, 64(5):471-478.
55. Tang WJ, Hu CP, Chen MF, et al. Epigallocatechin gallate preserves endothelial function by reducing the endogenous nitric oxide synthase inhibitor level [J]. Can J Physiol Pharmacol 2006, 84(2):163-171.
56. Negishi H, Xu JW, Ikeda K, et al. Black and green tea polyphenols attenuate blood pressure increases in stroke-prone spontaneously hypertensive rats [J]. J Nutr 2004, 134(1):38-42.
57. Ross R, Glomset JA Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis [J]. Science 1973, 180(4093):1332-1339.
58. Schwartz SM, de Blois D, O'Brien ER The intima. Soil for atherosclerosis and restenosis [J]. Circ Res 1995, 77(3):445-465.
59. Visse R, Nagase H Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry [J]. Circ Res 2003, 92(8):827-839.
60. Lindner V, Reidy MA Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor [J]. Proc Natl Acad Sci USA 1991, 88(9):3739-3743.
61. De Donatis A, Comito G, Buricchi F, et al. Proliferation versus migration in platelet-derived growth factor signaling: the key role of endocytosis [J]. J Biol Chem 2008, 283(29):19948-19956.
62. Won SM, Park YH, Kim HJ, et al. Catechins inhibit angiotensin II-induced vascular smooth muscle cell proliferation via mitogen-activated protein kinase pathway [J]. Exp Mol Med 2006, 38(5):525-534.
63. El Bedoui J, Oak MH, Anglard P, et al. Catechins prevent vascular smooth muscle cell invasion by inhibiting MT1-MMP activity and MMP-2 expression [J]. Cardiovasc Res 2005, 67(2):317-325.
64. Kim CH, Moon SK Epigallocatechin-3-gallate causes the p21/WAF1-mediated G(1)-phase arrest of cell cycle and inhibits matrix metalloproteinase-9 expression in TNF-alpha-induced vascular smooth muscle cells [J]. Arch Biochem Biophys 2005, 435(2):264-272.
65. Ahn HY, Hadizadeh KR, Seul C, et al. Epigallocathechin-3 gallate selectively inhibits the PDGF-BB-induced intracellular signaling transduction pathway in vascular smooth muscle cells and inhibits transformation of sis-transfected NIH 3T3 fibroblasts and human glioblastoma cells (A172) [J]. Mol Biol Cell 1999, 10(4):1093-1104.
66. Yuan X, Zhang Z, Gong K, et al. Inhibition of reactive oxygen species/extracellular signal-regulated kinases pathway by pioglitazone attenuates advanced glycation end products-induced proliferation of vascular smooth muscle cells in rats [J]. Biol Pharm Bull 2011, 34(5):618-623.
67. Ouyang P, Peng WL, Xu DL, et al. Green tea polyphenols inhibit advanced glycation end product-induced rat vascular smooth muscle cell proliferation [J]. Acad J First Med Coll PLA 2004, 24(3):247-251.
68. Yamamoto M, Acevedo-Duncan M, Chalfant CE, et al. Acute glucose-induced downregulation of PKC-betaII accelerates cultured VSMC proliferation [J]. Am J Physiol Cell Physiol 2000, 279(3):C587-C595.
69. Yang J, Han Y, Sun H, et al. (-)-Epigallocatechin gallate suppresses proliferation of vascular smooth muscle cells induced by high glucose by inhibition of PKC and ERK1/2 signalings [J]. J Agric Food Chem 2011, 59(21):11483-11490.
70. Jagroop IA, Kakafika AI, Mikhailidis DP Platelets and vascular risk: an option for treatment [J]. Curr Pharm Des 2007, 13(16):1669-1683.
71. Born GV Platelets in thrombogenesis: Mechanism and inhibition of platelet aggregation [J]. Ann Roy Coll Surg Engl 1965, 36:200-206.
72. Ueno M, Kodali M, Tello-Montoliu A, et al. Role of platelets and antiplatelet therapy in cardiovascular disease [J]. J Atheroscler Thromb 2011, 18(6):431-442.
73. Kang WS, Lim IH, Yuk DY, et al. Antithrombotic activities of green tea catechins and (-)-epigallocatechin gallate[J]. Thromb Res 1999, 96(3):229-237.
74. Yang JA, Choi JH, Rhee SJ Effects of green tea catechin on phospholipase A2 activity and antithrombus in streptozotocin diabetic rats [J]. J Nutr Sci Vitaminol (Tokyo) 1999, 45(3):337-346.
75. Son DJ, Cho MR, Jin YR, et al. Antiplatelet effect of green tea catechins: a possible mechanism through arachidonic acid pathway [J]. Prostagland Leukot Essent Fatty Acids 2004, 71(1):25-31.
76. Kang WS, Chung KH, Chung JH, et al. Antiplatelet activity of green tea catechins is mediated by inhibition of cytoplasmic calcium increase [J]. J Cardiovasc Pharmacol 2001, 38(6):875-884.
77. Serafini M, Laranjinha JA, Almeida LM, et al. Inhibition of human LDL lipid peroxidation by phenol-rich beverages and their impact on plasma total antioxidant capacity in humans [J]. J Nutr Biochem 2000, 11(11-12):585-590.
78. Murakami T, Ohsato K Dietary green tea intake preserves and improves arterial compliance and endothelial function [J]. J Am Coll Cardiol 2003, 41(6s1):271.
79. Kim W, Jeong MH, Cho SH, et al. Effect of green tea consumption on endothelial function and circulating endothelial progenitor cells in chronic smokers [J]. Circ J 2006, 70(8):1052-1057.
80. Oyama J, Maeda T, Kouzuma K, et al. Green tea catechins improve human forearm endothelial dysfunction and have antiatherosclerotic effects in smokers [J]. Circ J 2010, 74(3):578-588.
81. Wang ZM, Zhou B, Wang YS, et al. Black and green tea consumption and the risk of coronary artery disease: a meta-analysis [J]. Am J Clin Nutr 2011, 93(3):506-515.
82. Nagaya N, Yamamoto H, Uematsu M, et al. Green tea reverses endothelial dysfunction in healthy smokers [J]. Heart 2004, 90(12):1485-1486.
83. Pearson DA, Frankel EN, Aeschbach R, et al. Inhibition of endothelial cell mediated low-density lipoprotein oxidation by green tea extracts [J]. J Agric Food Chem 1998, 46:1445-1449.
84. Sung H, Min WK, Lee W, et al. The effects of green tea ingestion over 4 weeks on atherosclerotic markers [J]. Ann Clin Biochem 2005, 42(Pt 4):292-297.
85. Tang FY, Meydani M Green tea catechins and vitamin E inhibit angiogenesis of human microvascular endothelial cells through suppression of IL-8 production [J]. Nutr Cancer 2001, 41(1-2):119-125.
86. Vlachopoulos C, Alexopoulos N, Dima I, et al. Acute effect of black and green tea on aortic stiffness and wave reflections [J]. J Am Coll Nutr 2006, 25(3):216-223.
87. Sano J, Inami S, Seimiya K, et al. Effects of green tea intake on the development of coronary artery disease [J]. Circ J 2004, 68(7):665-670.
88. Hollman PC, Tijburg LB, Yang CS Bioavailability of flavonoids from tea [J]. Crit Rev Food Sci Nutr 1997, 37(8):719-738.
89. Meng X, Sang S, Zhu N, et al. Identification and characterization of methylated and ring-fission metabolites of tea catechins formed in humans, mice, and rats [J]. Chem Res Toxicol 2002, 15(8):1042-1050.
90. Manach C, Williamson G, Morand C, et al. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies [J]. Am J Clin Nutr 2005, 81(1 Suppl):230S-242S.
91. Manning J, Roberts JC Analysis of catechin content of commercial green tea products [J]. J Herb Pharmacother 2003, 3(3):19-32.
92. Nakagawa K, Okuda S, Miyazawa T Dose-dependent incorporation of tea catechins, (-)-epigallocatechin-3-gallate and (-)-epigallocatechin, into human plasma [J]. Biosci Biotechnol Biochem 1997, 61(12):1981-1985.
93. Chow HH, Hakim IA, Vining DR, et al. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals [J]. Clin Cancer Res 2005, 11(12):4627-4633.